Aptamer Group plc is a United Kingdom-based global developer of aptamer-based ligands. The Company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA).
Company Information
About this company
Key people
Arron C. Tolley
Chief Executive Officer, Executive Director
Andrew Rapson
Chief Financial Officer, Secretary
David H. Bunka
Chief Scientific Officer, Executive Director
Adam Hargreaves
Independent Non-Executive Chairman of the Board
Tim Sykes
Independent Non-Executive Director
Click to see more
Key facts
- Shares in issue2.70bn
- EPICAPTA
- ISINGB00BNRRP542
- LocationUnited Kingdom
- SectorTechnology
- IndustrySoftware & Programming
- Market cap£24.27m
- Employees31
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.